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Abstract: Background: IgA nephropathy is the most common primary glomerulonephritis in pregnancy
and shares with other immunologic diseases and kidney diseases a relationship with adverse maternal
outcomes, whose entity and pattern is only partially quantified. Recent studies provide new information
and a systematic review regarded progression of kidney disease. The discussion of the outcomes with
respect to low-risk pregnancies may help to perfect the estimation of the risks, and to identify specific
research needs. Methods: A search strategy was built on Medline, EMBASE and the Cochrane
review for the period January 2000–April 2017, aimed at retrieving both case series (defined as
with at least 6 pregnancies in women with IgA nephropathy) and case reports, to look into rare
occurrences. All papers, with or without control groups, were selected if they reported on at least
one pregnancy outcome, or on long-term kidney function. Search strategy, paper selection and data
extraction were done in duplicate (PROSPERO N 42016042623). Meta-analysis of case series was
performed with Metanalyst Beta 3.13. Case reports were analysed narratively. Results: The search
retrieved 556 papers, of which 27 were included (13 series and 14 case-reports). The case series report
on 581 women with 729 pregnancies. The analysis was performed in comparison to the available
control groups: 562 non-pregnant controls were available for the analysis of progression of kidney
disease. As for pregnancy related outcomes (preeclampsia (PE), pregnancy induced hypertension
(PIH), preterm birth, small babies), we meta-analyzed the data with respect to the only series of
low-risk pregnancies (1418 pregnancies). When compared with women who never got pregnant
after diagnosis of IgA nephropathy, in the present meta-analysis pregnancy in women with IgA
nephropathy was not associated with a higher risk of progression of kidney disease, possibly due to
the overall preserved kidney function at baseline: end-stage kidney disease (OR 0.68; CI 0.28–1.65).
Conversely, the incidence of adverse pregnancy-related outcomes was increased compared to low-risk
controls: PE and PIH were more than ten-fold increased (OR 11.80; CI 7.53–18.48 and OR 10.39;
CI 5.45–19.80), while the increase in risk of preterm birth and “low birth weight babies” was less
marked (OR 3.37; CI 1.91–5.95 and OR 2.36; CI 1.52–3.66), a discrepancy suggesting the occurrence of
“late” or “maternal” PE, that may affect less severely foetal growth or shorten gestation. In conclusion,
in the present meta-analysis IgA nephropathy was not associated with an increased progression of
kidney disease. The more than ten-fold increased risk of PIH and PE, in combination with a doubled
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risk of small babies, suggests the occurrence of “late” or “maternal” PE, usually less affecting early
foetal growth. This finding may be of help in defining control policies, while further research is
needed to guide clinical management.
Keywords: IgA nephropathy; pregnancy; preeclampsia; proteinuria; preterm delivery; systematic review
1. Introduction
IgA nephropathy is probably the most common primary glomerular nephritis worldwide; its
higher incidence in young people makes it highly relevant in pregnancy [1].
The present term of IgA nephropathy encompasses two previously defined diseases, usually
known by their eponyms: Berger’s disease, in which the IgA deposition is limited to the kidney, and
Henoch-Shönlein, in which IgA nephropathy is a part of a systemic vasculitis that could involve the
skin and the gastro-intestinal tract, with asymmetric acute osteoarthritis [2,3]. The recognition of
family clustering of the two diseases, and the identical renal pathology led to gather both diseases
under a unifying definition [4–6]. IgA nephropathy may present with a wide spectrum of clinical
presentations, from mild, recurrent and remittent microhematuria to boosts of macrohematuria and
nephritic syndrome, or a severe and rapidly progressive disease [1,4,7,8]. Hypertension and proteinuria
are considered as negative outcome predictors, even if only mild. Their negative effect on outcome
is observed even in the absence of reduced renal function, which is a likewise (albeit tautological)
acknowledged progression marker itself. Other histological markers of disease progression and risk
are still subject of debate [7–14]. The risk of progression to end stage renal disease (ESRD) has been
differently evaluated. However, this risk is not negligible over the entire life span as progression
to ERSD is reported from rare to frequent, depending on morphological, clinical and laboratory
characteristics, and treatment. For these reasons, IgA nephropathy is usually considered as a disease
that may remit, but that is never completely cured [14–18].
The acknowledgement of the importance of early renal disease in pregnancy is particularly
relevant for IgA nephropathy, due to its relatively high prevalence in young age, slow progression,
with frequent preservation of the kidney function at least for long periods, making normal kidney
function common in affected patients in childbearing age, and heterogeneous presentation, that may
impair early diagnosis [19–22].
As will be further discussed in detail, a systematic review, encompassing a wide time span, was
recently focused on the progression of chronic kidney disease in patients with IgA nephropathy who
had been pregnant [23]. To try to further add to the knowledge in this important field, we considered
several recent publications, not available at the time of the first review, and we focused a second
systematic review on the effect of IgA nephropathy on pregnancy and of pregnancy on the progression
of IgA nephropathy, on the new millennium, on the account of the changes in disease management
and maternofetal care occurring over time, and we attempted for the first time a meta-analytical
comparison with a low-risk population, in order to better quantify the risk of the various adverse
pregnancy outcomes, as a further support for counseling.
2. Methods
2.1. Eligibility Criteria
The eligibility criteria were broad, because of the expected retrieval of heterogeneous designs
and definitions. Consequently, we included all published studies that dealt with IgA nephropathy
in pregnancy and that reported on at least one pregnancy-related outcome, or on long-term kidney
function. We included all study designs, i.e., prospective or retrospective cohort studies, case-control
studies, trial-based analyses, and case reports. Reviews, whether or not systematic, were also gathered
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to check for papers eventually escaped from our wide search strategy. The search was not limited to
papers which provided a control group, but information on all control groups were gathered.
Studies were divided into those regarding more than 5 or less than 6 cases (defined as case series
and cases reports, respectively).
The review was prospectively registered on PROSPERO International prospective register of
systematic reviews (N 42016042623).
The review was performed according to the Meta-analysis of observational studies in
epidemiology (MOOSE) criteria.
2.2. Search Strategy
We searched MEDLINE, PubMed, Embase and the Cochrane Review database from January 2000
to April 30th 2017 using a combination of MeSH terms and keywords related to IgA nephropathy and
pregnancy, including: pregnancy, pregnant, gestation* and IgA nephropathy, Henoch* or Shoenlein*,
Berger*. We also checked the reference lists of relevant articles and citations of included studies.
We did not limit our search to any language, but we limited it to the period starting from 2000,
allowing for the considerable changes in management of the disease and in maternofetal follow-up
that occurred in the new millennium, in order to implement the clinical decision rules presently
recommended by the very few guidelines or consensus statements dealing with glomerular diseases in
pregnancy [24–26].
All articles identified were screened for eligibility on the basis of the content only: all papers
reporting on any form of IgA nephropathy in pregnancy and reporting on any outcome were selected.
The search was performed by G.B.P. and I.A.K., after which I.A.K. and R.A. did a first screening of
the papers. The final selection was agreed between G.B.P. and I.A.K., any discrepancy was resolved
by discussion.
2.3. Data Extraction and Quality Assessment
Two reviewers (I.A.K. and G.B.P.) extracted study and population characteristics and outcomes.
A third reviewer (G.C.) double-checked the accuracy of data entered from each study in case of
discrepancies. All definitions of IgA nephropathy, pre-eclampsia (PE), pregnancy induced hypertension
(PIH), small babies, small for gestational age babies (SGA) or other pregnancy related outcomes
were gathered.
Due to the lack of randomized controlled trials (RCTs), and to the limited number and type
of control groups, no formal analysis of risk of bias was performed. No selection for quality was
performed. However, the studies were critically analyzed and the completeness of the data was
considered as an indirect marker of quality.
The case series were compared with the controls available, regarding progression of chronic kidney
disease (CKD), and with the only low risk population available, regarding the various pregnancy
outcomes. Odds ratios and confidence intervals were calculated (OR, CI). The case reports were
described narratively.
2.4. Data Synthesis
The PICOS criteria were adapted to this particular situation in which pregnancy is considered the
“intervention” as follows:
P—Patients: women with IgA nephropathy in pregnancy;
I—Intervention: in the absence of a true “intervention”, pregnancy was considered as the
“intervention”;
C—Comparators: in the case of progression of kidney disease, non-pregnant IgA patients were
considered as comparators. In the case of pregnancy outcomes, considered low-risk pregnancies or
pregnancies in women not affected by IgA nephropathy (or other kidney diseases);
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O—Outcomes: progression of kidney disease; all the materno-fetal outcomes described in the
papers (including, but not limited to, PE, PIH, preterm delivery, small babies, SGA).
S—Studies: all studies, regardless of the study design, reporting on pregnancy outcomes or on
long-term kidney function in patients with IgA nephropathy.
Statistical analysis was performed using Metanalyst Beta 3.13.
Due to the high baseline heterogeneity a random effect model was employed.
Stratification for baseline renal function, hypertension and proteinuria was attempted, but was
not possible due to the high heterogeneity of the papers.
The control groups retrieved mainly regarded progression of kidney disease in women with IgA
nephropathy who did not get pregnant after diagnosis; these data were used to analyze the effect of
pregnancy on kidney function.
For pregnancy-related outcomes, we employed as a control group the only low-risk population
available (from the cohort named TOCOS from the Torino Cagliari Observational Study) and
meta-analyzed each study with respect to it.
3. Results
3.1. Case Series: Overall Data
The search strategy identified 556 articles, of which 27 met the inclusion criteria: 13 case series,
which we attempted to meta-analyze, for the various outcomes, and 14 case reports, discussed
narratively (Figure 1) [27–53].
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The main characteristics of the case series are reported in Tables 1–4 [27–39].
Overall, the case series included four prospective studies, eight retrospective studies and
two matched cohort studies, the latter regarding progression of CKD in women affected by IgA
nephropathy, with or without pregnancy (Table 1). Globally, the studies report on 581 women with
729 pregnancies in IgA nephropathy (assuming one pregnancy per woman if not otherwise specified),
and on 562 non-pregnant controls distributed over three studies; conversely, normal pregnancies were
available in only one study [30].
The studies are heterogeneous for the number of pregnancies (12 to 229), setting of study (seven
from Asia, five from Europe, one from the USA and one from Saudi Arabia), and study aims. Six
studies provided information on the type and frequency of control policies in pregnancy and during
follow-up (Table 2).
3.2. Case Series: Pregnancy Outcomes
Table 3 reports on the main pregnancy-related outcomes reported in the papers. Given the
different study designs, the included studies reported on different outcomes: neonatal deaths were
reported on by 4 studies, live births were reported on by 8 studies, preterm delivery was reported
by 8, and need for admission to neonatal intensive care unit by one study only. All studies reported
on preeclampsia (PE) and/or hypertensive disorders of pregnancy. Information on birth weight was
available in most studies, but the information was not always contextualized to gestational age, and
the information on neonates small for gestational age was available in two studies only.
Overall, the papers describe a population with high incidence of PIH (reported in around 30% of
the cases, however, the distinction with preexisting hypertension is usually lacking, and this leads to a
possible underestimation of new onset hypertension) and PE (reported in around 15% of the cases),
with about 15% incidence of preterm deliveries, usually without exhaustive specification of gestational
age (Table 3).
Table 4 reports on baseline kidney function and other maternal outcomes: baseline kidney function
(glomerular filtration rate: GFR) was relatively well preserved in most studies but was fully normal in
2 only (GFR was >100 mL/min in 2 studies and <100 mL/min in 7 studies). Mean proteinuria was
around 1 g/day. Prevalence of hypertension was not clearly defined at baseline, and the distinction
between previous use of angiotensin converting enzyme-inhibitors (ACEi) or Angiotensin II receptor
blockers (ARBS) for proteinuria, hypertension or both was not available.
Four of five studies reporting on kidney function over time did not find any difference between
cases and non-pregnant controls during follow-up, considering however different outcomes (start
of dialysis, doubling of serum creatinine, GFR decrease, new-onset hypertension); the fifth, most
recent study, found a correlation between kidney function worsening and the occurrence of adverse
pregnancy outcomes [27] (Table 4).
3.3. Case Reports
The main characteristics of the case reports are summarized in Tables 5–7 [40–53].
Keeping in mind the aim to discuss severe or unusual situations, the cases reported on various
situations, including new onset-diagnosis of IgA nephropathy in pregnancy, recurrence of IgA
nephropathy in a kidney allograft, severe reduction of the kidney function (5 cases); one case reported
on three pregnancies in the same woman (one occurring in the pre-dialysis phase, two on dialysis)
(Table 5).
Presumably as a consequence of the different selection of the cases compared to that of the
series, most of the babies were born preterm (61.5%); maternal complications were common (30%)
and more than half of the newborns had low birth weight. Nevertheless, all reported babies had
a favorable outcome. Conversely, dialysis was needed in pregnancy in three cases and half of the
patients developed hypertension or preeclampsia.
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Table 1. IgA nephropathy: Main characteristics of the case series (at least 6 pregnancies).
Author Year [Ref] Years Country Study Objective, as Stated in the Study Pregnancies (P)
§§
Women (W)
Park 2017 [27] 1979–2015 Korea Ret To assess the relationship between pregnancy and renal prognosis in women with IgAN and toinvestigate further whether obstetric complications are associated with renal prognosis
59 W
64 P
59 W controls (non-pregnant IgA)
O’Shaughnessy 2017 [28] 1996–2015 USA Ret To investigate the influence of glomerular disease subtype on pregnancy outcomes 17 W18 P
Su 2017 [29] 2003–2014 China Pro To assess the effects of pregnancy on kidney disease progression and risk factors for adversepregnancy outcomes in patients with IgAN
104 W
116 P
309 W controls (non-pregnant IgA)
Tocos 2017 [30] 2000–2016 Italy Pro To evaluate the maternofetal outcomes in different glomerulonephritis
27 W §
33 P
1418 P controls (low risk)
Liu 2014 [31] 2003–2012 China Matched-cohort To evaluate the safety of pregnancy in women with IgAN, as well as their risk factors for adversepregnancy outcomes, as compared to non-pregnant women with IgAN
62 W
69 P
62 W controls (non-pregnant IgA)
Oh 2011 [32] 2004–2009 Korea Ret
To investigate whether higher proteinuria at conception predicts a faster decline in maternal
renal outcomes and to identify whether a proteinuria reduction prior to pregnancy attenuates the
deterioration of postnatal maternal outcomes
52 W
Suetsugu 2011 (**) [33] NR Japan Ret To explore the clinical characteristics of predictive factors for hypertension in biopsy-proven IgAnephropathy patients with superimposed preeclampsia 34 W
Shimizu 2010 [34] 1995–2006 Japan Pro To evaluate the impact of the CKD staging in patients with IgAN on pregnancy and delivery
29 W
29 P
45 W controls (non-pregnant IgA)
Waness 2010 [35] 2000–2006 SaudiArabia Pro
To examine the natural history of pregnancies and their impact on renal function in Saudi
females affected by IgAN
12 W
12 P
Limardo 2010 [36] 1974–2003 Italy Ret multicentercohort
To compare the long-term outcome of kidney disease in women with IgAN and preserved
kidney function (sCr <1.2 mg/dL) who did and did not become pregnant. Data on 10 pregnant
and 12 non pregnant women with sCr >1.2 mg/dL also gathered
136 W
229 P
87 W controls (non-pregnant IgA)
Donggyu 2010 (*) [37] 1987–2008 Korea Ret To clarify the influence of pregnancy on the natural course of IgAN 25 W28 P
Ronkainen 2006 [38] NR Finland Ret To evaluate renal survival, morbidity, pregnancy complications and factors predicting outcomeafter childhood IgAN
10 W
22 P
Ronkainen 2002 [39] NR Finland Ret To assess long-term outcome of children with renal involvement at onset of Henoch-Schönleinpurpura by comparison with those who have mainly extra-renal symptoms at referral
14 W
23 P
Overall number of women, pregnancies and controls
581 W
729 P §
562 non pregnant IgA controls
1418 low risk controls
CKD: chronic kidney disease; IgAN: IgA nephropathy; NR: not reported; P: pregnancy; Pro: prospective; Ret: retrospective; sCr: serum creatinine; W: woman. * Abstract only (congress
proceeding); (**) paper in Japanese, abstract used. § not mentioned in article, additional information available in original database §§ if number of pregnancies not specified, we assumed 1
pregnancy per woman.
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Table 2. IgA nephropathy: maternal and fetal control policies, in the papers reporting on them (Case Series).
Author Year [Ref] Control Policies
Su 2017 [29] Follow up at least once a month before delivery, and every 1–6 months after delivery, with minimum follow up 12 months postpartum or until dialysis treatment
Tocos 2017 [30] Follow up at least once monthly if proteinuria, hypertension or kidney function reduction
Liu 2014 [31] Follow up every ≤1 month; eGFR decline; determination time-averaged MAP and proteinuria every 3 months
Shimizu 2010 [34] BP, proteinuria, blood analysis and eGFR at the baseline at the time of detection of pregnancy; at 16, 22 and 30 weeks of pregnancy; at the time of delivery; and at 3months and 1, 2 and 3 years after delivery
Waness 2010 [35] Monthly measures of BP, 24 h proteinuria, sCr, CCr; close monitoring and follow up
Limardo 2010 [36] Information gathered at time of biopsy and every 5 year thereafter: CCr, 24 h proteinuria, body weight, BP, therapy with ACEIs/ARBs or immunosuppressants
Donggyu 2010 (*) [37] sCr followed up max 3 years after delivery
ACEI: ACE-inhibitor; ARB: angiotensin II-receptor blocker; BP: blood pressure; CCr: creatinine clearance; eGFR: estimated glomerular filtration rate, assessed by MDRD or EPI formula;
IgAN: IgA nephropathy; MAP: mean arterial pressure; NR: not reported; sCr: serum creatinine; * Abstract only.
Table 3. IgA Nephropathy: Fetal and pregnancy outcomes in the case series.
Author Year [Ref]
All Cases Considered Live Births Only All Cases All Cases, or As Stated
P
Abort.
Spont.
Induced
Still Birth Live Birth Neo. Death
Preterm <37 weeks
Early <34 weeks
Extreme <28 weeks
NICU PE-HT Other
Park 2017 [27] 64 NR NR NR NR Preterm: 21 (33%)Early: 8 (13%) NR PE: 13 (20%)
LBW <2500 g: 16 (25%)
LBW <1500 g: 6 (9%)
SGA <10th: 6 (9%)
O’Shaughnessy 2017
[28] 18 NA 0 18 (100%) 2 (11%)
Preterm <37 w: 6 (33%), 5/6
induced/CS on maternal
indication
Preterm <32 w: 4 (22%)
NR PE: 6 (33%)
Median GA: 37.5 week (36–39)
Median BW: 2627 g (2136–3315)
IUGR <10th: 2 (11%)
IUGR<3rd: 0
Apgar 1 min: 8 (7–9)
Apgar 5 min: 9 (9–9)
Su 2017 [29] 116 5 (4%) spont2 (2%) induc 18 (16%) 90 (78%) 1 (1%) Preterm: 13 (11%) NR
GHT: 26/89 (29%)
Severe PE: 12 (10%)
PtU >3.5 g/day:
19/110 (17%)
CS: 62 (53%)
Mean GA: 37.8 week ± 2.4
Mean BW: 3035 g ± 668 †
LBW <2500 g: 16 (17%) †
LBW <1500 g: 3 (3%) †
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Table 3. Cont.
Author Year [Ref]
All Cases Considered Live Births Only All Cases All Cases, or As Stated
P
Abort.
Spont.
Induced
Still Birth Live Birth Neo. Death
Preterm <37 weeks
Early <34 weeks
Extreme <28 weeks
NICU PE-HT Other
Tocos 2017 [30]
33 cases NA NA 33 (100%) NR
Preterm: 12 (36%)
Early: 4 (12%) ††
Extreme: 1 (3%) ††
NR GHT: 7/24 (29%)
†††
PE: 4/17 (24%) †††
CS: 9 (27%)
LBW: 10 (30%)
SGA <10th: 4 (12%) ††
SGA <5th: 1 (3%) ††
1418 controls NA NA 1418 (100%) NR
Preterm: 89 (6%)
Early: 13 (1%)
Extreme: 2 (0.1%)
NR HT: 66 (5%)PE: 25 (2%) PtU: 25 (2%)
CS: 379 (27%)
GA: 39 weeks (25–42)
BW: 3232 ± 476 g
SGA <10th: 120 (8%)
SGA <5th: 45 (3%)
Liu 2014 [31] 69 8 (12%) § 2 (3%) 59 (86%) NR Preterm: 7 (10%) NR
Severe PE:
6 W (10%)
CS: 42 (61%)
LBW: 8/59 (14%)
Mean BW: 2972 ± 654 g
Oh 2011 [32] 52 §§ NR NR NR Preterm: 8 (15.4%) 4 (7.7%) HT: <8 weeks31 (60%)
CS: 24 (46.2%)
LBW: 13 (25%)
Suetsugu 2011 (**) [33] 34 NR NR NR 1 (3%) NR NR Superimp. PE: 13 (38.2%) BW negatively correlated withglomerular sclerosis, sCr and BUN.
Shimizu 2010 [34] 29 0 0 29 (100%) 0 0Gestation 38.0 ± 2 weeks NR No PE
CS: 5 (17.2%)
BW: 2911.2 ± 138.7 g
LBW: 0
Waness 2010 [35] 12 0 0 12 (100%) NR 0 NR
HT: 12 (100%)
PE: 3 (25%)
HELLP: 1 (8.3%)
CS: 2 (HELLP and PE)
BW: 3.1 kg
LBW: 0
Apgar: normal (1’ and 5’)
Limardo 2010 [36] 229 15 spon13 indu 5 (2.2%) 195 (85%) 1 (0.4%) Preterm: 20 (10%) NR
HT: 43/201 (21%)
PE: 17 W (13%)
Mean BW: 3039 ± 610 g
LBW: 22/195 (11%)
Donggyu 2010 (*) [37] 28 NR NR NR NR NR NR PE: 4 W (of 5 with sCr>2.0 mg/dL) NR
Ronkainen 2006 [38] 22 At least 2spont NR 20 NR
Preterm: at least 6 (30%)
Extreme: at least 2 (10%) NR
HT: 10 (46%)
Severe PE: 1 W (10%)
PtU: 12 (55%)
6 (30%) of 20 live born infants from
mothers with HT and/or
proteinuria premature
Ronkainen 2002 [39] 23 NR NR NR NR NR NR HT and/or PtU: 16 (70%) NR
Summary data 729 45/485 (9.3%) 25/473 (5.3%) 456/528(86.3%) 5/426 (1.2%)
Preterm 95/608 (15.6%)
Early: 18/135 (13.3%)
Extreme: 3/53 (5.6%)
4/52 (7.7%) PIH: 98/348 (28.2%)PE: 79/523 (15.1%)
CS: 144/311 (46.3%)
LBW: 85/530 (16.0%)
IUGR/SGA <10th: 12/115 (10.4%)
abort: abortions (<24 gestational weeks); W: women; BUN: blood urea nitrogen; BW: birth weight; CS: caesarean section; m: months; NR not reported; HELLP: hemolysis, elevated liver
enzymes, low platelets syndrome; HT: hypertension; LBW: low birth weight (<2500 g); NA: not applicable, only included births >20 weeks or only live births; NICU: neonatal intensive
care unit; NR: not reported; PE: preeclampsia; P: pregnancies; PtU: proteinuria; sCr: serum creatinine; * Abstract only (**) paper in Japanese, abstract used, † data on 86/116 pregnancies, ††
not mentioned in article, additional information available in original database, ††† calculated in W without baseline hypertension and/or proteinuria, § spontaneous abortion: 1 (2%);
induced abortion: 1 (2%); embryo damage 3 (4%); fetal malformation 3 (4%)., §§ 14 abortions in 80 women, not included in final analyses of the study. Note: if not otherwise clarified,
numbers of cases with hypertension, PE and/or PtU were counted separately.
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Table 4. IgA Nephropathy. Kidney function and other maternal outcomes in the case series reporting on them.
Author Year [Ref] Age (years) Kidney Function at Baseline Other Maternal Outcomes and Main Results
Park 2017 [27]
28 (24–31) (cases)
eGFR: 80.0 (61.0–105.6)
sCr: 0.90 mg/dL (0.70–1.00)
PtU: 1.09 g/day (0.46–2.02)
HT: 36 (61%)
Renal survival rate with gestational complications: 55.3% at 10 y; 46.1% at 20 years
Renal survival rate without gestational complications: 97.3% at 10 y; 97.3% at 20 years
Obstetric complications (PE, LBW and/or preterm birth), not pregnancy itself, associated with CKD
progression, especially if eGFR <60, preexisting HT and PtU >1 g/day (all significant)
26 (23–32) (controls)
eGFR: 85.0 (64.7–102.0)
sCr: 0.80 mg/dL (0.70–1.00)
PtU: 0.87 g/day (0.43–1.60)
HT: 33 (56%)
Renal survival rate: 80.3% at 10 years; 70.4% at 20 years
O’Shaughnessy 2017 [28] 31.3 (23.0–33.8)
eGFR: 72 (61–90) (9/18 P)
sCr: 1.0 mg/dL (0.8–1.2) (9/18 P)
PtU spot: 1.3 g (0.9–4.1) (8/18 P)
≥200% increase PtU (2–12 m postpartum): 2/6 (33.3%)
≥150% increase sCr (2–12 m postpartum): 1/8 (12.5%)
ESRD 1 year postpartum: 2 (11.1%) §
Active IgAN during pregnancy: 12 (66.7%). Dialysis during pregnancy: 0
Su 2017 [29]
27.2 ± 3.5 (cases)
eGFR: 102.6 ± 23.9
PtU: 1.04 g/day (0.03–7.25)
HT: 15 (14%)
Follow up: 67 ± 34 months
Persistent HT postpartum: 12/89 (13%). Irreversible PtU worsening: 7 (6%)
PtU at pregnancy start or first trimester: risk factor for severe PE and infant loss
ESRD: 4 (4%) § ESRD/>50% decrease eGFR: 7 (7%)
Significant decrease kidney function after pregnancy in CKD stage 3–4 only
28.7 ± 6.3 (controls)
eGFR: 94.5 ± 26.7
PtU: 1.29 g/day (0.02–11.78)
HT: 52 (17%)
Follow up: 65 ± 34 months
ESRD: 18 (6%) §
ESRD/>50% decrease eGFR: 31 (10%)
Tocos 2017 [30]
31.9 ± 5.2 (cases)
eGFR: 89.9 ± 32.7
sCr: 0.87 mg/dL (0.50–2.88)
PtU ≥0.5 g/day: 13 (41%)
HT: 9 (27%)
Worsening CKD stage during pregnancy: 1/33 (3%) §§
Increased risk of PE but not of preterm delivery suggests late maternal PE
31.2 ± 5.5 (controls) HT: none
Liu 2014 [31]
27.3 ± 3.6 (cases)
eGFR: 102.3 ± 21.9
PtU: 1.27 (0.06–7.25) g/day
HT: 7 (11%)
HT after pregnancy 8 (13%); MAP during follow up 86.4 ± 8.6
Kidney disease progression: 4 (6%); decrease eGFR >50%: 3 (5%); ESRD: 1 (2%) §
Mean change eGFR: −2.5 mL/min (−6.7 to 0.06)
PtU during follow up: 0.67 g/day (0.10–6.72)
Proteinuria in pregnancy borderline significant for adverse pregnancy outcomes
27.8 ± 4.4 (controls)
eGFR: 103.4 ± 20.8
PtU: 1.09 (0.06–8.37) g/day
HT: 4 (6%)
MAP during follow up 85.4 ± 7.3; Kidney disease progression: 6 (10%)
decrease eGFR >50%: 4 (7%); ESRD: 2 (3%) § Mean change eGFR −2.4 –−7.1 to 2.4) mL/min
PtU during follow up: 0.68 (0.07–4.30) g/day
Oh 2011 [32] 30.5 (25.0–39.0) eGFR: 91.2 (24.1–157.0) mL/minMAP: 89.6–99.3 mmHg
eGFR after delivery 77.8 (19.8–150.0)
Median ∆GFR with ≤30% reduction proteinuria prior to conception: 13%
Median ∆GFR with >30% reduction proteinuria prior to conception: 8.7%
MAP during pregnancy 96.7–102
Significant increase sCr (0.8–1.0 mg/dL) and PtU (0.7–1.5 g/g) after delivery
Suetsugu 2011 (*) [33] NR NR
Superimposed PE: preconception SBP, sCr, BUN higher; CCr and eGFR lower
Delivery: sCr, BUN, uric acid higher; CCr and eGFR lower (significant)
At delivery correlation between BP and histological severity, proteinuria and sCr
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Table 4. Cont.
Author Year [Ref] Age (years) Kidney Function at Baseline Other Maternal Outcomes and Main Results
Shimizu 2010 [34]
27.3 ± 4.0 (cases)
eGFR mL/min
CKD1: 97.3 ± 9.4
CKD2: 74.1 ± 4.5
CKD3: 54.4 ± 11.6
eGFR 3 year after delivery (mL/min): CKD1: 93.0 ± 1.6; CKD2: 78.2 ± 11.8; CKD3: 58.5 ± 14.4; Overall:
baseline 68.9 ± 14.4—three years after 68.5 ± 14.9
sCr baseline—3 year after delivery (mg/dL): 1: 0.68–0.64; 2: 0.75–0.72; 3:0.94–0.90. Overall: 0.83 ±
0.20–0.75 ± 0.14
PtU baseline—3 year after delivery (g/day): CKD1: 0.19 ± 0.1–0.20 ± 0.28; CKD2: 0.39 ± 0.22–0.48 ± 0.44;
CKD3: 0.77 ± 0.31–0.38 ± 0.33 (**)
BP constant in all CKD groups
28.1 ± 5.1 (controls) eGFR: 70.9 ± 20.7
eGFR after 3 years (mL/min): 68.6 ± 14.4
sCr baseline—after 3 years (mg/dL): 0.8 ± 0.15–0.88 ± 0.16.
PtU baseline—after 3 years (g/day): 0.85 ± 0.65–0.40 ± 0.26
No new onset hypertension
Waness 2010 [35] 28.6
CCr 88.6 mL/min
sCr: 0.99 mg/dL
BP: 128.2/82.1 mmHg
PtU 535.2 mg/day
In 3rd trimester: BP 163.7/90.3 mmHg
PtU 2179.2 mg/day
CCr 77.4 mL/mins
Cr 84.3 mmol/L
Limardo 2010 [36]
26.72 ± 4.27 (cases)
sCr 0.87 ± 0.15
CCr 92 ± 17
PtU 1.0 (0–6) g/day
HT: 27 (20%)
After 10 years: 36% on steroids and/or immuno-depressors; 61% on ACEI or ARBs
Significant CCr decrease (−1.2 mL/min/year) in women with PtU >1 g/day at diagnosis, not modified by
number of pregnancies, hypertension, PE
Doubling of sCr in 13 (9.6%); start of dialysis in 3 (3.4%) §; new-onset HT in 34 (31%) of 109 previously
normotensive women
26.19 ± 5.15 (controls)
sCr 0.86 ± 0.16
CCr 89 ± 18
PtU 0.5 (0–7.6) g/day
HT: 10 (11%)
After 10 years: 29% on steroids and/or immune-depressors; 47% on ACEI or ARBs
Doubling of sCr in 7 (8%); start of dialysis in 2 (1.5%) §; new-onset HT in 16 of 77 (21%) previously
normotensive women
Donggyu 2010 * [37] NR NR
PE in 4 of 5 women with sCr >2.0 mg/dL at delivery
ESRD within 2 years in 2/2 W with sCr >2.5 mg/dL in postpartum
All women with sCr <2.5 mg/dL in postpartum had stable sCr 3 year after delivery
Ronkainen 2006 [38] NR NR ESRD 2.6 year after delivery in 1 hypertensive woman with slightly impaired renal function beforepregnancy §
Ronkainen 2002 [39] NR NR HT or PtU in pregnancy: 9 (64.3%), of whom 5 reported poor outcome (not specified); no poor outcomereported in women without HT or PtU in pregnancy
Summary data baseline
GFR or CCr >100 mL/min in 2/9 study reporting on this item
GFR <100 mL/min in 7/9 studies
PtU ≥0.5 g/day in 6/7; <0.5 g /day in 1/7 studies (**)
Hypertension in 11–61% in 4 studies, in other not clearly defined at baseline
Summary data progression
ESRD: 11/330 (3.3%) cases vs 22/458 (4.8%) controls, reported on by 5 studies of whom 3 provided a control group §
Park: no significant difference between cases and non-pregnant controls. Significant better renal survival in cases without vs with obstetric complications, and in cases without obstetric
complications vs non pregnant controls
Su: no significant difference in incidence ESRD or eGFR decrease between cases and non-pregnant controls
Liu: no difference between cases and non-pregnant controls over follow-up
Shimizu: no difference in eGFR decrease between pregnancy and non-pregnancy
Limardo: no significant difference in all outcomes (start of dialysis, doubling of serum creatinine, new onset hypertension)
BP: blood pressure; CCr: creatinine clearance; (e)GFR: (estimated) glomerular filtration rate; ESRD: end-stage renal disease; HT: hypertension; MAP: mean arterial pressure; NR: not
reported; P: pregnancies; PE: preeclampsia; PtU: proteinuria; sCr: serum creatinine. * Abstract only (*) article in Japanese, abstract used. ** discrepant data between the various CKD stages
and overall, as for proteinuria: Overall: 0.86 ± 0.80–0.56 ± 0.48. § used in meta-analysis despite of difference in follow-up (1 to 10 years); §§ not mentioned in article, additional information
available in original database.
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Table 5. IgA Nephropathy. Case reports: baseline data.
Author Year [Ref] Country Age (years) sCr-GFR-PtU Other Data at Referral Main Drugs in Pregnancy
Kaul 2016 * [40] India
NR NR IgAN new-onset Steroids, fish oil
NR NR IgAN new-onset Steroids, fish oil
NR NR IgAN new-onset Steroids, fish oil
Lim 2016 * [41] USA NR NR IgAN (diagnosed severalyears postpartum) NR
Sun 2015 [42] China 26 PtU 1–2+ IgAN new-onset NR
Nagai 2015 [43] Japan 37 PtU postpartum HSPN postpartum NR
Liang 2015 * [44] USA 32 PtU 2 g/day IgAN new-onset NR
Zand 2014 [45] USA 18 sCr 1.8 mg/dL IgAN NR
Cornelis 2013 [46] The Netherlands 21 CCr 20–25 mL/min IgAN Methyldopa, labetalol, EPO, thyroid hormones, oral iron
Hou 2013 [47] USA 28 CCr 79 mL/minPtU 1.13 g/day IgAN new-onset
Methyldopa, labetalol, hydralazine, magnesium (31 week), steroid
prophylaxis (31 week)
Goifrè 2007 [48] Italy
25 sCr 2.2 mg/dLPtU 1 g/day IgAN
ASA, oral iron, vitamins, vaginal dinoprostone gel (36 week)
30 sCr 8 mg/dL EPO, vit D, calcium carbonate, ritodrin (29 week)
32 HD EPO, vit D, calcium carbonate, ritodrin (30 week)
Tanno 2007 [49] Japan 31 sCr 0.8 mg/dL HSPN recurrence in renalallograft
Methyldopa, amlodipine
Immunosuppressors (not clear)
Barquero-Romero 2006 [50] Spain 36 sCr 0.50 mg/dLPtU 1+ HSPN new-onset Methylprednisolone
Koizumi 2004 [51] Japan 30 PtU + HSPN new-onset Low dose oral steroids for 3 week
Cusi 2003 [52] Italy 29 sCr 1.5 mg/dLPtU 1.2 g/day IgAN Methyldopa, nifedipine, clonidine, EPO, steroid prophylaxis (26 week)
Amir 2002 (*) [53] Saudi Arabia NR sCr 2.7 mg/dLPtU 5.4 g/day IgAN with P-ANCA Cyclophosphamide, prednisone
Summary data 28.8 (18–37)
sCr <1.0 mg/dL: 2/9 (22.2%)
sCr ≥1.0 mg/dL: 5/9 (55.6%)
CCr <90 mL/min: 2/9 (22.2%)
CCr ≥90 mL/min: 0
PtU >= 0.5 g/day: 5/5 (100%)
reporting quantitatively
IgAN: 12 (new-onset: 6)
HSPN: 4 (new-onset: 3)
Antihypertensive agent: 4/10
Immunosuppressors: 4/10
ASA: acetyl salicylic acid; CCr: creatinine clearance; EPO: Erythropoietin; GFR: Glomerular filtration rate; h: hours; HSPN: Henoch-Schönlein purpura nephropathy; IgAN: IgA
nephropathy; i.v.: intravenous; methyldopa: alpha-methyldopa; NR: Not reported; PtU: proteinuria; sCr: serum creatinine; vit: vitamin; w: week. * Abstract only (*) abstract used.
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Table 6. IgA Nephropathy. Case reports: fetal outcomes.
Author Year [Ref] Pts GW Parity Delivery Indication for Delivery NICU APGAR 1–5 minInfant Outcomes Sex Weight (g) Centile *
Kaul 2016 * [40] 3 NR NR NR NR NR All live births NR NR NR
Lim 2016 * [41] 1 NR NR NR NR NR NR NR NR NR
Sun 2015 [42] 1 40 Primi CS NR NR NR NR NR NR
Nagai 2015 [43] 1 At term NR Vaginal None NR NR NR NR NR
Liang 2015 * [44] 1 36 + 5
Gravi 7
Para 1
P1051
Vaginal
induced
Presumed superimposed
PE NR NR F NR NR
Zand 2014 [45] 1 32 NR Vaginal None NR Healthy M NR NR
Cornelis 2013 [46] 1 36 Primi Vaginalassisted Sudden HT YES
9 and 10
Wet lung syndrome, NICU non-invasive
ventilatory support 1 day. Discharged 8
days later.
M 2480 25
Hou 2013 [47] 1 31 Gravi 2Para 0 CS PE, failed induction NR
3 and 8
Normal development 11 years later. F 1596 64
Goifrè 2007 [48] 1
38 Gravi 1Para 0 Vaginal None YES
8 and 9
NICU, discharged 20 days later. M 3150 45
33 Gravi 2Para 1 CS NR YES
7 and 8
NICU for RD (ventilatory support for 6
h); discharged 20 days later.
M 2190 65
33 Gravi 3Para 2 CS NR YES
5 and 8
NICU for RD (ventilatory support for 2
days); discharged 30 days later.
M 2500 90
Tanno 2007 [49] 1 28 NR CS Impaired umbilical flowand fetal growth NR No obvious anomalies NR 999 39 **
Barquero-Romero
2006 [50] 1 39 Multi Vaginal None NR Healthy at 3 m follow up M 3380 41
Koizumi 2004 [51] 1 40 Primi Vaginal None NR Healthy M 2986 11
Cusi 2003 [52] 1 31 NR Vaginal None NR 8 and 9Healthy F 1626 68
Amir 2002 (*) [53] 1 NR NR NR NR NR NR NR NR NR
Summary data 16 (18cases)
<37 w: 8/13
(61.5%)
≥37 w: 5/13
(38.5%)
Primi: 4/9
(44.4%)
Multi: 5/9
(55.6%)
Vaginal:
8/13 (61.5%)
CS: 5/13
(38.5%)
Maternal complications:
3/10 (30%)
Fetal complications: 1/10
(10%)
None: 6/10 (60%)
All reported cases had favorable outcomes; NICU
reported in 4 cases
F: 3/10
(30%)
M:
7/10
(70%)
<2500 g: 5/9
(55.6%);
<1500 g: 1/9
(11.1%)
AGA: 9/9
(100%)
(calculated
upon INeS
charts)
AGA: appropriate for gestational age; CS: cesarean; d: days; F: female; Gravi: gravidity; GW: Week of gestation; h: hours; HT: hypertension; LGA: large for gestational age; M: male; m:
months; Multi: multipara; NICU: neonatal intensive care unit; NR: not reported; Para/P: parity; PE: preeclampsia; Primi: primipara; Pts: Patients; RD: respiratory distress; w: weeks. *
Abstract only (*) abstract used * Centiles calculated according to the INeS charts (reference). If parity or sex are not specified: male sex and primipara considered.
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Table 7. IgA Nephropathy. Case reports: maternal outcomes.
Author Year [Ref] PE/Other Maternal Outcomes, as Reported in the Paper
Kaul 2016 * [40] NR All 3 patients treated with steroids and fish oil, complete remission in all 3 patients
Lim 2016 * [41] HT and PtU at 22 weeks, presumed PE. No follow up postpartum. Several years postpartum (age 25) presentation with severe HT and cardiac failure, pulmonary edema, hematuria,proteinuria, small hypo-echoic kidneys on ultrasound. Kidney biopsy: IgAN with severe atrophy and fibrosis
Sun 2015 [42] None 5 days postpartum atypical hemolytic uremic syndrome (AKI, nephrotic syndrome,thrombocytopenia and hemolytic anemia), HD for 5 weeks
Nagai 2015 [43] 6th month HSP purpura, during pregnancy normal urinalysis 1 m postpartum HSPN without renal dysfunction, and anti-PL-7 anti-synthetase syndrome with interstitial lungdisease and subclinical myopathy
Liang 2015 * [44] HT, proteinuria and hematuria Normalization BP; persistent PtU and hematuria; biopsy proven IgAN 1.5 years later
Zand 2014 [45] HT, anemia, atypical hemolytic uremic syndrome, start HD On HD; living kidney donor transplant 5 months later
Cornelis 2013 [46] 26 week start intensive HD for rapidly progressive deterioration kidneyfunction; sudden HT 35 + 5 weeks 2 weeks postpartum restart HD; 1 year later living-donor kidney transplant
Hou 2013 [47] HT, PE 31 weeks 1 year later deterioration kidney function; 11 years later evaluation for kidney transplant
Goifrè 2007 [48]
Anemia Pre HD (CKD in 1st pregnancy)
Anemia; start HD end 1st trimester; polyhydramnios 28 weeks On HD
Anemia, polyhydramnios 30 weeks On HD; 1 year later: kidney transplant
Tanno 2007 [49] 17 week HT and PtU, microhematuria; worsening of kidney function at24 weeks and 28 weeks
Postpartum decrease BP and sCr, PtU from 6.0 to 1.0 g/day 6 months postpartum
kidney biopsy: HSPN recurrence in renal allograft with additional focal segmental membranous nephropathy with
C1q deposition
Barquero-Romero 2006 [50] HSP at 36 weeks, good response to steroid Healthy at 3 months follow up
Koizumi 2004 [51] Elevated levels CRP and ALT/AST Normalization of blood analysis and urinanalysis
Cusi 2003 [52] HT, anemia Persistence of HT and anemia
Amir 2002 (*) [53] 11 week rapidly progressive GN: sCr 2.7 mg/dL, PtU 5.4 g/24 h Good response to cyclophosphamide and prednisone: sCr 1.4 mg/dL, PtU 0.516 g/day, 18 months after diagnosisno significant clinical problems and stable kidney function
Summary data
PE: 1
Pregnancy induced HT: 6
Start HD in pregnancy: 3
Different outcomes of the kidney function also depending upon the disease
AKI: acute kidney injury; BP: blood pressure; CRP: C-reactive protein; d: days; GN: glomerulonephritis; HD: hemodialysis; HT: hypertension; HSPN: Henoch-Schönlein purpura
nephropathy; IgAN: IgA nephropathy; NR: Not reported; PE: preeclampsia; PtU: proteinuria; * Abstract only (*) abstract used.
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3.4. Meta-Analysis
Kidney Function
Figure 2 reports on ESRD and the start of renal replacement therapy in patients with and without
pregnancy. The incidence was low in the five studies reporting on this outcome: 11/330 patients
versus 22/458 controls, and there was no significant difference found between the two groups (OR 0.68;
CI 0.28–1.65).
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Figure 2. Odds ratio for end-stage renal disease in patients with IgA nephropathy, with or without
pregnancy. Legend: ESRD: end stage renal disease. CI: confidence intervals.
These reassuring data have to be contextualized to patients with good renal function, and it has
to be taken into account that time of follow up differed notably between the studies (ranging from 1 to
10 years postpartum), which reduces the clinical value of this comparison (Figure 2).
3.5. Pregnancy Related Outcomes
The risk for adverse pregnancy-related outcomes was higher in IgA patients than in the low-risk
cohort (Figure 3).
While the incidence of caesarean sections and the incidence of small for gestational age babies
were not significantly different in IgA nephropathy and in the low-risk control group, the odds ratio for
preterm delivery, PE and PIH were significantly higher for women with IgA nephropathy (Figure 3).
Odds ratio (OR) for PE and PIH were particularly high: PE: OR 11.80; CI 7.53–18.48, PIH OR
10.39; CI 5.45–19.80. Conversely, the risk of preterm birth was about threefold that of the low-risk
population (OR 3.37; CI 1.91–5.95), while the risk of neonates with low birth weight is about twice as
high (OR 2.36; CI 1.52–3.66).
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4. Discussion
This systematic review identified 13 cases series and 14 case reports, reporting on pregnancy-related
outcomes in IgA nephropathy [27–53]. This is, at the b st of o r knowledge, the largest umber of papers
meta-analyzed or narratively discussed on IgA nephropathy in pregnancy, with particular attention to
the risk of adverse pregnancy-related outcomes. In this regard, our review may add information to a
previous recent systematic review, which included papers published since the start of Medline, and
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was mainly focused on the progression of kidney disease in patients with IgA nephropathy with and
without pregnancy [23]. The review, that selected 4 papers with a control group, providing data of
273 patients with IgA nephropathy and of 241 patients with IgA nephropathy who did not become
pregnant, supported a lack of disadvantage on the progression of nephropathy for IgA nephropathy
patients with well-preserved function that became pregnant.
The main novelty of the present review is to give more insight into the risk of pregnancy-related
outcomes, that were already reported as frequent by the previous study, but that are meta-analyzed for
the first time with respect to a low-risk population; in this context, limiting the analysis to the studies
published since 2000 may allow for a better contextualization in the present panorama (Figure 3).
The pattern of pregnancy-related outcomes is complex and the behavior of the risks may offer
some interesting insights into the pathogenesis of pregnancy complications in IgA nephropathy. In fact,
the meta-analysis identifies a particularly high risk of PE and PIH in women with IgA nephropathy,
with an over ten-fold increase, within wide but consistent confidence intervals (Figure 3). In spite of
these high odds ratios, the significantly increased risk of preterm birth was only about triple compared
to the low-risk population and the incidence of newborns with low birth weight is only doubled,
while no difference was found in the incidence of both caesarean sections and of small for gestational
age babies (Figure 3). This finding suggests that the very high risk for hypertensive disorders of
pregnancy is not accompanied by a correspondent increase of preterm babies, and of babies whose
growth has been severely impaired, as it occurs in the “placental” early forms of preeclampsia, and
therefore suggests that the related event occurs later, corresponding with the so-called “late” form
of PE [54–58]. Such a form of PE is usually milder, and is often associated with maternal diseases,
and indeed some authors distinguish between “maternal” and “placental” preeclampsia, the latter
characterized by a primary defect of placentation, and frequently associated with intrauterine growth
restriction. Conversely, the maternal form is more often of late onset, frequently, even if not always,
less severe, and is associated with a lower risk of newborns that are small for gestational age, a pattern
that may be consistent with the observations gathered in the present review [54–59].
With respect to disease progression, the lack of negative effect of pregnancy, at least in populations
with relatively preserved kidney function, reported in the previous meta-analysis, is confirmed by
our analysis, performed with a different, selection of the papers, and with the chance of adding
several recent studies on this issue (Figure 2) [23]. In most of the studies retrieved by both reviews
kidney function was normal or well-preserved before pregnancy and, in this context, the progression
of the kidney disease does not appear to be affected by pregnancy. However, most studies fail to
give information both on women with severe CKD and the duration of the observation time is not
always clear. Furthermore, even if relatively long, the median follow-up period of 10 years described
by Limardo, and of 4.5 years by Liu, could still be too short to draw conclusions, given the slow
progression of early IgA nephropathy [31,36]. The interesting new suggestion that progression of
kidney disease is limited to the cases who display adverse pregnancy outcomes should be confirmed
in further studies [27].
The case reports, as expected, focus on exceptional events, and are probably affected by reporting
and publishing biases. Despite these limits, they may underline that positive pregnancy outcomes are
possible, even in severe advanced chronic kidney disease [40–53] (Tables 5–7).
The major strength of this study is that it provides an updated systematic review in one of the most
common nephropathies observed in young patients all over the world, gathering over 700 pregnancy
published in the new millennium, and attempting, for the first time, a risk assessment with regard
to the overall population. The integration with case reports, a further novel aspect of this review,
underlines that a positive outcome is possible even in women with severe CKD, who are usually
excluded from the larger case series.
The main limitations of this review are linked to the heterogeneity of the studies in terms of
populations, definitions and outcomes, as well as duration of follow-up. Heterogeneity is a common
problem in systematic reviews on CKD pregnancies, which limits the value of the meta-analysis,
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and calls for a common language, a still unmet goal [60–62]. Furthermore, due to lack of data on
low-risk populations, we employed the only available one, from a multicenter Italian study; the
approach of choosing a reference population for a wider meta-analysis is not new, and was for example
employed by Deshpande and coworkers in the pivotal analysis on pregnancy after kidney or after
liver transplantation, which plotted the data against the reference USA population [63,64]. Such a
choice is an obvious compromise, and the lack of matched populations limits the precision of the
comparison; however, the differences with the low-risk populations are highly significant, and their
pattern is consistent, thus allowing at least posing new hypotheses and indications for future research.
Within these limits, we hope that our findings may be of interest for counseling and for tailoring
clinical surveillance for clinicians working in obstetrics and in nephrology.
Our study may also indicate uncovered fields for future research. First of all, more data is needed
to better define the risk of adverse pregnancy outcomes, particularly so in case of kidney function
decrease. Secondly, given the impossibility to clinically distinguish an increase in proteinuria and
hypertension related to the IgA nephropathy from that related to preeclampsia, there is need for precise
description of these cases, with stratification for previous hypertension, and univocal definitions of
superimposed PE. In this regard, IgA nephropathy may represent a field for the systematic use of old
and new biomarkers of PE and kidney disease [63–68].
5. Conclusions
Patients with IgA nephropathy and severe CKD should be informed about the paucity of data
allowing a precise quantification of the risks. In patients with preserved kidney function, that represent
the majority of those reported, the risk of progression of kidney disease is low, and may be limited to
the cases who display adverse pregnancy related events. Conversely the risk of developing PE and
PIH is very high compared to the low-risk population (OR > 10). The pattern of these hypertensive
disorders of pregnancy, associated with a significant but milder increase in preterm delivery but not of
small for gestational age babies, suggests the presence of late onset PE, in its “maternal” form, thought
to affect fetal growth less severely than ‘placental’ early PE. This hypothesis, needing confirmation on
a larger scale, may prove of interest in interpreting the increase in hypertensive disorders of pregnancy
observed in chronic kidney disease.
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